Eaton’s Vehicle Group Launches Electric Vehicle E-Drive Gearing Design, Development and Manufacturing
Power management company Eaton today announced its Vehicle Group is developing gearing solutions for electrified vehicles (EVs). Leveraging its expertise in producing transmissions and contract manufactured gear-sets for passenger and commercial vehicles, the Vehicle Group aims to be a leader in the global design, development and supply of EV reduction gearing. The new technology complements Eaton’s eMobility power electronics portfolio in the electrified vehicle powertrain market.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210218005131/en/
Eaton’s Vehicle Group can partner with customers on joint-development programs or serve as a single service provider of EV reduction gearing components or systems. (Photo: Business Wire)
Eaton meets electrified vehicle challenges
Automakers face many challenges when developing an electrified vehicle, such as optimizing efficiency, weight, noise, vibration and harshness (NVH), and dealing with packaging constraints. Eaton can help manufacturers meet these challenges by applying its many years of experience and in-house capability in design, validation and manufacturing of high-precision, high-quality gearing systems for transmissions and powertrains.
“We are partnering with OEM customers to leverage our expertise in simulation, design and manufacturing to optimize the efficiency, NVH and weight of high-precision gearing systems tailored to specific customer needs,” said Anthony Cronin, director, EV gearing, Eaton’s Vehicle Group.
Whether a large-scale industrialization project or a niche-market application, Eaton can partner with customers on joint-development programs or serve as a single service provider of EV reduction gearing components or systems. Eaton’s expertise in both design and manufacturing allows us to optimize solutions from a technical, commercial and production aspect, reducing the risk of multi-iteration design and enabling shortened development times.
Eaton transmission experience drives efficiency
Eaton conducts a total system analysis, using state-of-the-art tools and in-house expertise, to design EV gearing solutions that are optimized for efficiency and reliability, with low noise and manufacturing costs. A full-system approach is essential when tailoring a design to a specific customer need, as several factors influence the development of gearing solutions. Chief among those factors are the gears, bearings and lubrication system. To achieve optimization in these three areas, Eaton applies a series of in-house design and manufacturing techniques, including:
- Gear root geometry optimization for maximum strength.
- Micro and macro gear geometry modelling to improve NVH, efficiency and reliability.
- Thrust load and bearing loss minimization to improve reliability and simplify or downsize bearings.
- Simulation and selection of lubrication solutions for full-system reliability and efficiency.
Optimized transmission lowers development costs
Eaton engineers evaluate existing layouts or develop “clean-sheet” solutions that work within a customer’s packaging constraint. The Eaton team also provides solutions for scaling the EV gearing layout for platforms with multiple torque requirements.
By combining system design expertise and manufacturing know-how in high-quality precision gears, Eaton has identified opportunities to improve gearing system efficiency by up to 1 percent, reduce weight by up to 20 percent and size by up to 10 percent. These benefits can be applied to both light-duty and commercial electrified vehicles.
Additionally, by applying its manufacturing expertise, including power honing, power skiving, grinding and superfinishing, Eaton can manage the relative production cost of high-quality precision gears. With electrified vehicles, even small efficiency improvements provide vehicle manufacturers new opportunities to manage vehicle range or improve cost and weight.
“The development of EVs is pushing the boundaries of EV gearing. Reliable, efficient and quiet gearing systems are critical to high-speed motor adoption in electric drives,” said Cronin.
Learn more about Eaton’s Vehicle Group EV Gearing solutions.
Eaton’s mission is to improve the quality of life and the environment through the use of power management technologies and services. We provide sustainable solutions that help our customers effectively manage electrical, hydraulic, and mechanical power – more safely, more efficiently, and more reliably. Eaton’s 2020 revenues were $17.9 billion, and we sell products to customers in more than 175 countries. We have approximately 92,000 employees. For more information, visit www.eaton.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210218005131/en/
Contact information
Thomas Nellenbach
thomasjnellenbach@eaton.com
(216) 333-2876 (cell)
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Compass Pathways Announces FDA Acceptance of IND Application for PTSD and Hosts Webinar on PTSD and TRD7.1.2026 13:30:00 EET | Press release
Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation, today announced that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for COMP360, enabling the initiation of a late-stage clinical trial in patients with PTSD. Compass management, along with KOL and industry leaders, will host a webinar today to discuss the company’s clinical trial plans for PTSD, as well as commercial preparations for treatment-resistant depression (TRD) from 10:00-11:30 am ET on January 7th. “PTSD is one of the most challenging mental health conditions, with approximately 13 million adults in the U.S. living with persistent symptoms and limited treatment options,” said Dr. Guy Goodwin, Chief Medical Officer at Compass Pathways. “We are pleased to advance our clinical development - the unmet need is profound, and it demands bold innovation. We believe COMP360 has the potential to tra
Stallergenes Greer Expands Venom Immunotherapy Production Capacity With Acquisition of Entomon s.r.l.7.1.2026 12:07:00 EET | Press release
Stallergenes Greer, a global leader in allergy therapeutics, today announced that it has entered into an agreement to acquire Entomon s.r.l., an Italian company specialising in the production of certified stinging-insect venom extracts, notably of the Hymenoptera order, used for the manufacture of diagnostic preparations and Venom Immunotherapy (VIT). The transaction is expected to close by the end of January. Entomon, currently recognised as the only company in Europe capable of extracting pure venom from Hymenoptera insects, produces pharmaceutical-grade insect venom using proprietary techniques (Entomon Capillary Extracted Venom®) for medical use. Through this acquisition, Stallergenes Greer bolsters its venom manufacturing capabilities and supply of raw materials for life-saving VIT treatments, whilst safeguarding patient care continuity. Hymenoptera venom allergy is the most common trigger of severe anaphylaxis in adults1. According to the EAACI guidelines on venom immunotherapy,
ARIS Announces New CEO to Lead Agentic AI-led Strategy7.1.2026 11:00:00 EET | Press release
CEO Appointment ARIS, a global leader in process intelligence and transformation software, today announced the appointment of Guillaume Bacuvier as Chief Executive Officer. Guillaume will lead ARIS through its next phase of growth as a fully standalone company, accelerating its evolution from a market leader in Process Intelligence into a foundational platform for enterprises deploying and governing Agentic AI. Guillaume brings deep international leadership experience across technology, data, and software-enabled businesses, with a proven track record of scaling global platforms and leading complex organisations. After starting as a strategic consultant at Booz Allen Hamilton, Guillaume spent over a decade at Google, rising to Vice President in EMEA where he built and scaled some of Google’s largest data-driven businesses in Europe and held P&L responsibility across multiple countries. In the last decade, Guillaume has served as CEO of multi-continent, data-centric companies including
I Squared Capital Acquires Ramudden Global, a Leader in Traffic Management and Infrastructure Safety7.1.2026 10:00:00 EET | Press release
I Squared Capital, a leading global infrastructure investment manager, today announced that, through its flagship fund, it has agreed to acquire Ramudden Global, from funds advised by Triton Partners (“Triton”), a leading European mid-market sector-specialist investor. Ramudden Global is a leading international provider of traffic management and infrastructure safety services supporting the maintenance and upgrade of essential transport and utility networks. The company operates more than 190 depots across 13 countries in Europe and North America delivering mission-critical services that help to ensure safety, regulatory compliance and continuity of service across road, utility and broader infrastructure works. This investment underscores I Squared Capital’s commitment to investing in essential, regulated, infrastructure businesses that underpin public safety, mobility and economic activity. Ramudden operates in markets where demand is steady and growing and benefits from deep commerci
RoslinCT and BOOST Pharma Announce Strategic Manufacturing Agreement to Advance Cell Therapy for Infants with Osteogenesis Imperfecta7.1.2026 10:00:00 EET | Press release
RoslinCT, a global contract development and manufacturing organization (CDMO) specializing in advanced cell therapies, and BOOST Pharma, a clinical-stage biotechnology company developing first-in-class cell therapies for rare paediatric skeletal diseases, today announced a strategic manufacturing partnership to support the development of BOOST Pharma’s cell therapy, BT-101, for the treatment of infants with Osteogenesis Imperfecta (OI), also known as brittle bone disease. Under the service agreement, BOOST Pharma has transferred its manufacturing process to RoslinCT’s state-of-the-art facilities in Edinburgh, Scotland. The partnership will progress toward GMP manufacturing of starting materials and clinical drug product, supporting Phase III clinical development of BT-101. The therapy is an allogeneic mesenchymal stem cell (MSC) product designed to address the underlying cause of OI at the earliest stages of life. BOOST Pharma was founded on pioneering science originating from Karolins
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom